Nivolumab plus ipilimumab in the treatment of advanced melanoma

被引：0
作者：
Katy K. Tsai
Adil I. Daud
机构：
[1] University of California,Helen Diller Comprehensive Cancer Center
来源：
Journal of Hematology & Oncology | / 8卷
关键词：
Melanoma; Immunotherapy; PD-1; CTLA-4; Nivolumab; Ipilimumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Advanced melanoma has historically been a difficult disease to treat due to few effective systemic treatment options. However, over the past few years, scientific advancements in immune checkpoint inhibition have resulted in several novel approaches that have changed front-line management of advanced melanoma. Despite these exciting developments, there remains room for improvement in treatment outcomes. Combination immunotherapy, in particular combined cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1) blockade, represents an important first step in this direction.
引用
收藏
相关论文
共 56 条
[1]  
Krummel MF(1995)CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation J. Exp. Med. 182 459-65
[2]  
Allison JP(1996)CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells J. Exp. Med. 183 2533-40
[3]  
Krummel MF(1992)Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death EMBO J. 11 3887-95
[4]  
Allison JP(2013)A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application Nat. Immunol. 14 1212-8
[5]  
Ishida Y(2010)PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors Proc. Natl. Acad. Sci. 107 4275-80
[6]  
Agata Y(2015)Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo J. Immunol. 194 950-9
[7]  
Shibahara K(2013)Nivolumab plus ipilimumab in advanced melanoma N. Engl. J. Med. 369 122-33
[8]  
Honjo T(2015)Nivolumab and ipilimumab versus ipilimumab in untreated melanoma N. Engl. J. Med. 372 2006-17
[9]  
Okazaki T(2015)Combined nivolumab and ipilimumab or monotherapy in untreated melanoma N. Engl. J. Med. 373 23-34
[10]  
Chikuma S(2010)Improved survival with ipilimumab in patients with metastatic melanoma N. Engl. J. Med. 363 711-23
123456